| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 21 Nov 2024 | 15 Nov 2024 |
| VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/11/2024 inter alia to consider and approve the Vivo Bio Employees Stock Option Scheme 2024 (VBESOS 2024) in terms of SEBI (Share Based Employee Benefits and Sweat Equity) regulations 2021. With reference to the above cited subject and our letter dated November 15, 2024, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. Thursday, November 21, 2024, inter-alia, transacted the following business: 1. Pursuant to the recommendations of the Nomination and Remuneration Committee (NRC), approved the Vivo Bio Employees Stock Option Scheme, 2024 (VBESOS, 2024) for grant of stock options to eligible Directors and Employees of the Company and its Group Company(ies) including its Subsidiary / Associate Company(ies) (Present and Future, if any), subject to approval of the shareholders of the Company, as per SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 [SEBI (SBEBSE) Regulations, 2021]. The Company shall seek the approval of Members through postal ballot (As per BSE Announcement Dated on 21/11/2024) | ||
| Board Meeting | 14 Nov 2024 | 29 Oct 2024 |
| Quarterly Results Please find enclosed Unaudited Financial Results for the Quarter and Half Year ended September 30, 2024 (As Per BSE Announcement Dated on: 14/11/2024) | ||
| Board Meeting | 26 Aug 2024 | 26 Aug 2024 |
| Please find enclosed Outcome of the Board Meeting | ||
| Board Meeting | 10 Aug 2024 | 1 Aug 2024 |
| VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2024 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30 2024. Please find enclosed Unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2024 (As Per BSE Announcement Dated on: 10/08/2024) | ||
| Board Meeting | 18 Jun 2024 | 18 Jun 2024 |
| With reference to the above cited subject, and pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, (Listing Regulations), and based on the recommendation of the Audit Committee, the Board of Directors of the Company at their meeting held today, i.e. Tuesday, June 18, 2024, inter-alia, transacted the following business: 1. Approved the Notice of Postal Ballot recommending to the shareholders, for appointment of Mr. Viswanath Kompella, Promoter, as an advisor of the company. This is for your information and records. | ||
| Board Meeting | 20 May 2024 | 6 May 2024 |
| VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2024 inter alia to consider and approve Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31 2024. With reference to above cited subject, we bring to your kind notice that the Board of Directors at their meeting held today i.e., Monday, May 20, 2024, inter-alia, Approved the Audited Standalone and Consolidated Financial Results of the company for the fourth quarter and year ended March 31, 2024. (As Per BSE Announcement dated on 20.05.2024) | ||
| Board Meeting | 12 Feb 2024 | 30 Jan 2024 |
| VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 inter alia to consider and approve the Un-audited Standalone and Consolidated Financial Results for the Third Quarter and Nine Months ended December 31 2023. Please be informed that the trading window of Vivo Bio Tech Limited shall remain closed for all Directors Promoters Designated Employees and Specified Connected Persons of the Company till February 14 2024 in view of the aforesaid Board Meeting. This is for your information and records. With reference to the above cited subject and our letter dated January 30, 2024, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. Monday, February 12, 2024, inter-alia, transacted the following business: 1. Approved the Un-Audited Standalone & Consolidated Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2023. The meeting commenced at 06.00 p.m. and concluded at 07.15 p.m. This is for your information and records. (As per BSE Announcement Dated on 12/02/2024) | ||
| Board Meeting | 23 Jan 2024 | 23 Jan 2024 |
| Outcome of the Board Meeting - Intimation of Appointment of Mr. Vaishnavi Kiran Ayinampudi as the Company Secretary & Compliance Officer of the Company | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
